N-Power Medicine, a provider of a platform for clinical trials, has raised an undisclosed sum in a Series B funding round led by Merck Global Health Innovation Fund, with participation from a US-based healthcare-focused investor. This brings the total funds raised by the company to USD 72 million.

The raised funds will be used to expand N-Power's oncology clinic network. By year-end, N-Power plans to partner with six to eight oncology clinics and expects to have more than 100 oncologists in its network.

In addition to the funding, N-Power partnered with Merck to expand access to clinical trials for oncologists and patients. Through the partnership, Merck's clinical trials will be available across N-Power’s network sites, with two initial trials currently available.

Based in California, N-Power Medicine focuses on transforming clinical trials in oncology through its purpose-built clinical research platform. The company's main offering, the N-Power Platform, aims to accelerate drug development by enabling community oncology practices to conduct clinical trials more effectively by integrating research and standard care into a single workflow. N-Power additionally provides on-site and virtual staffing to support clinical research operations.